Apoptosis-Inducing Effect of 5-Aminolevulinic Acid-Mediated Photodynamic Therapy (5-ALA-PDT) on Cervical Cancer Cell Lines
Author(s): Gui-Fang He, Mei-Lu Bian, Ya-Wei Zhao, Qing Xiang, Hong-Yan Li and Cheng Xiao
5-Aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) is a new ablation treatment for tumors, while its function mechanism in
cervical cancer is unclear. This study was to investigate the effects of ALA-PDT on cervical cancer cell lines. METHODS: The effects of ALA-PDT on proliferation of
8 human cervical cancer cell lines were examined by MTT assay to find out the optimal function parameters of ALA-PDT and the most sensitive cell line. The effect
of ALA-PDT on apoptosis of cervical cancer cell line Me180 was investigated by using Annexin V-FITC/PI double staining, Hoechst 33342 staining and May-Grunwald-Farbstoff
Giemsa staining. Cell cycle of Me180 cells was observed by flow cytometry with PI staining. The effect of ALA-PDT on the expression of survivin in Me180 cells was detected
by Western blot and real-time fluorescence reverse transcription-polymerase chain reaction (RT-PCR). RESULTS: Among the 8 cell lines, Me180 cell line was most sensitive to
ALA-PDT; 2 mmol/L ALA, 10 J/cm2 light dose and 3-hour treatment were the optimal function parameters of ALA-PDT, and the 50% inhibition concentration (IC50) of ALA-PDT
under this situation for Me180 cells was 7.28×10-4 mmol/L. ALA-PDT induced apoptosis and G0/G1 phase arrest of Me180 cells, and suppressed the mRNA and protein expression
of survivin in Me180 cells. CONCLUSION: ALA-PDT can inhibit the proliferation and induce apoptosis of cervical cancer cell line Me180 in vitro, which may relate with the
suppression of survivin expression.
Oral 5-Aminolevulinic Acid Administration Allows Fluorescence of Cervix
Author(s): Gynecologic Oncology, 2002; 85: 125-128. "Detection of Female Lower Genital Tract Dysplasia Using Orally Administered 5-Aminolevulinic
Acid Induced Protoporphyrin IX: A Preliminary Study"
Oral administration of 5-aminolevulinic acid (5-ALA) allows fluorescence of the cervix in patients with abnormal Pap smears and is well tolerated
by patients. Investigators from Massachusetts General Hospital in Boston, United States, suggest, "Future study is needed to demonstrate the successful identification of
dysplastic lesions, with the ultimate goal of treating dysplasia of the lower genital tract with 5-ALA and light therapy."